Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Möbius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Jüni P, Fearon WF; FAME 2 Trial Investigators. De Bruyne B, et al. Among authors: kalesan b. N Engl J Med. 2012 Sep 13;367(11):991-1001. doi: 10.1056/NEJMoa1205361. Epub 2012 Aug 27. N Engl J Med. 2012. PMID: 22924638 Free article. Clinical Trial.
Percutaneous closure of patent foramen ovale in cryptogenic embolism.
Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton AS, Wahl A, Windecker S, Jüni P; PC Trial Investigators. Meier B, et al. Among authors: kalesan b. N Engl J Med. 2013 Mar 21;368(12):1083-91. doi: 10.1056/NEJMoa1211716. N Engl J Med. 2013. PMID: 23514285 Free article. Clinical Trial.
Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial.
Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Jüni P. Stefanini GG, et al. Among authors: kalesan b. Lancet. 2011 Dec 3;378(9807):1940-8. doi: 10.1016/S0140-6736(11)61672-3. Epub 2011 Nov 8. Lancet. 2011. PMID: 22075451 Free article. Clinical Trial.
Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts.
Taniwaki M, Räber L, Magro M, Kalesan B, Onuma Y, Stefanini GG, van Domburg RT, Moschovitis A, Meier B, Jüni P, Serruys PW, Windecker S. Taniwaki M, et al. Among authors: kalesan b. EuroIntervention. 2014;9(12):1432-40. doi: 10.4244/EIJV9I12A241. EuroIntervention. 2014. PMID: 24064377 Free article.
The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents.
Pilgrim T, Vetterli F, Kalesan B, Stefanini GG, Räber L, Stortecky S, Gloekler S, Binder RK, Wenaweser P, Moschovitis A, Khattab AA, Buellesfeld L, Zwahlen M, Meier B, Jüni P, Windecker S. Pilgrim T, et al. Among authors: kalesan b. Circ Cardiovasc Interv. 2012 Apr;5(2):202-10. doi: 10.1161/CIRCINTERVENTIONS.111.965749. Epub 2012 Mar 27. Circ Cardiovasc Interv. 2012. PMID: 22456025
Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial.
Räber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, Cook S, Moschovitis A, Vogel R, Kalesan B, Seiler C, Eberli F, Lüscher TF, Meier B, Jüni P, Windecker S. Räber L, et al. Among authors: kalesan b. Circulation. 2011 Jun 21;123(24):2819-28, 6 p following 2828. doi: 10.1161/CIRCULATIONAHA.110.004762. Epub 2011 Jun 6. Circulation. 2011. PMID: 21646500 Clinical Trial.
117 results